Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 13;12(4):63.
doi: 10.1038/s41408-022-00653-1.

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

Ajay K Nooka  1 , Jonathan L Kaufman  2 , Cesar Rodriguez  3 , Andrzej Jakubowiak  4 , Yvonne Efebera  5 , Brandi Reeves  6 , Tanya Wildes  7 , Sarah A Holstein  8 , Larry D Anderson Jr  9 , Ashraf Badros  10 , Leyla Shune  11 , Ajai Chari  12 , Huiling Pei  13 , Annelore Cortoos  14 , Sharmila Patel  14 , J Blake Bartlett  15 , Jessica Vermeulen  16 , Thomas S Lin  14 , Paul G Richardson  17 , Peter Voorhees  18
Affiliations

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

Ajay K Nooka et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

AKN served as a consultant for, received honoraria from, and received research funding from Janssen, Amgen, Takeda, Sanofi, Karyopharm Therapeutics, Bristol Myers Squibb, Oncopeptides, Adaptive, and Spectrum. JLK has served as a consultant for, received honoraria from, or received research funding from AbbVie, Amgen, Bristol Myers Squibb, Fortis Therapeutics, Heidelberg Pharma, Janssen, Novartis, Roche/Genentech, Sutro Biopharma, Takeda, and Tecnopharma; and has served as a member on the board of directors or advisory committees for Incyte and TG Therapeutics. CR has served as an advisor or speaker for Amgen, Bristol Myers Squibb, Janssen, Karyopharm, and Takeda. AJ held membership on an entity’s board of directors or served on advisory committees for Sanofi, Karyopharm, Janssen, GlaxoSmithKline, Amgen, AbbVie, Bristol Myers Squibb, Gracell, and Celgene. YE has received honoraria from Janssen, GlaxoSmithKline, Takeda, Oncopeptide, Alnylam, and Sanofi; served on a speakers bureau and/or as an advisor for Oncopeptide, Sanofi, Janssen, Takeda, Alnylam, and GlaxoSmithKline; and received research funding from Bristol Myers Squibb/Celgene. BR has received honoraria from Takeda and Incyte; served on a speakers bureau for Bristol Myers Squibb; and provided consultancy for and received honoraria from Pharma Essentia. TW has served as a consultant for Janssen, Carevive, Sanofi, and Seattle Genetics. SAH held membership on an entity’s board of directors or served on an advisory committee for Oncopeptides, Celgene, and Takeda; received honoraria from Celgene, Genentech, GlaxoSmithKline, Janssen, Secura Bio, Sorrento, and Takeda; and received research funding from Oncopeptides. LDA has served as a consultant for, received research funding or honoraria from, held membership on an entity’s board of directors or served on advisory committees for Amgen, Bristol Myers Squibb, Celgene, Janssen, GlaxoSmithKline, Janssen, Karyopharm, AbbVie, Prothena, and Oncopeptides. AB has received research funding from Bristol Myers Squibb and GlaxoSmithKline. LS has nothing to disclose. ACh held membership on an entity’s board of directors, or participated on advisory committees for AbbVie, Amgen, Bristol Myers Squibb/Celgene, Genentech, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Sanofi, Seattle Genetics, Secura Bio, Antengene, and Shattuck Labs; received research funding from Amgen, Bristol Myers Squibb/Celgene, Janssen, Seattle Genetics, Pharmacyclics, and Takeda/Millennium; and acted as a consultant for Amgen, AbbVie, Antengene, Bristol Myers Squibb/Celgene, Genentech, GlaxoSmithKline, Janssen, Karyopharm, Novartis, Sanofi, Secura Bio, Shattuck Labs, and Takeda/Millennium. HP, ACo, BB, and JV are current employees and stock shareholders of Janssen. SP is a current employee of Janssen. TSL is a current employee and stock shareholder of Janssen and holds stock in GlaxoSmithKline. PGR has received research funding from Celgene/Bristol Myers Squibb, Karyopharm, Oncopeptides, and Takeda; and has served on advisory committees for AstraZeneca, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Protocol Intelligence, Regeneron, Sanofi, and Secura Bio. PV has served as a consultant for, received honoraria from, or served as an advisory board member for AbbVie, Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm, Novartis, Oncopeptides, Pfizer, Sanofi, and Secura Bio.

Figures

Fig. 1
Fig. 1. Summary of response rates and MRD-negativity (10−5) rates over time in Black and White patients.
Response rates over time are shown for (A) Black patients (D-RVd, n = 14; RVd, n = 18) and (B) White patients (D-RVd, n = 82; RVd, n = 71) for the response-evaluable population, which included all randomized patients who had a confirmed diagnosis of multiple myeloma, measurable disease at baseline, received ≥1 dose of study treatment, and had ≥1 post-baseline disease assessment. Responses were assessed according to the IMWG criteria by computer algorithm, and rates of MRD negativity were measured by next-generation sequencing with a minimum sensitivity threshold of 1 in 105 cells or higher, in accordance with IMWG criteria [13, 14]. MRD negativity testing occurred at baseline, first evidence of suspected CR or sCR, the end of induction and consolidation, and after 12 and 24 months of maintenance, regardless of response. Data analysis occurred at the median follow-up of 27.4 months, after all patients completed ≥12 months of maintenance therapy or discontinued. MRD-negativity (10−5) rates over time are shown for (C) Black patients (D-RVd, n = 14; RVd, n = 18) and (D) White patients (D-RVd, n = 85; RVd, n = 76) in the intent-to-treat population. Percentages may not equal 100 due to rounding. D-RVd daratumumab plus lenalidomide/bortezomib/dexamethasone; RVd lenalidomide/bortezomib/dexamethasone; ASCT autologous stem cell transplant; sCR stringent complete response; CR complete response; VGPR very good partial response; PR partial response; SD stable disease; PD progressive disease; NE not evaluable; IMWG International Myeloma Working Group; MRD minimal residual disease.
See this image and copyright information in PMC

Comment in

References

    1. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116:679–86. doi: 10.1182/blood-2010-02-268862. - DOI - PMC - PubMed
    1. Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519–27. doi: 10.1016/S0140-6736(16)31594-X. - DOI - PMC - PubMed
    1. Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936–45. doi: 10.1182/blood.2020005288. - DOI - PMC - PubMed
    1. Kaufman JL, Rodriguez C, Reeves B, Nathwani N, Costa LJ, Lutska Y et al. Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of GRIFFIN after 12 months of maintenance therapy. Blood. 2020. 10.1182/blood-2020-137109.
    1. Fillmore NR, Yellapragada SV, Ifeorah C, Mehta A, Cirstea D, White PS, et al. With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood. 2019;133:2615–8. doi: 10.1182/blood.2019000406. - DOI - PMC - PubMed

Publication types